Mouse VEGFR2/KDR/Flk-1 Antibody

Catalog # Availability Size / Price Qty
AF644
AF644-SP
Mouse VEGFR2/KDR/Flk-1 Antibody in Data
3 Images
Product Details
Citations (48)
FAQs
Supplemental Products
Reviews

Mouse VEGFR2/KDR/Flk-1 Antibody Summary

Species Reactivity
Mouse
Specificity
Detects mouse VEGFR2 in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross-reactivity with recombinant human VEGFR2 is observed and less than 2% cross-reactivity with recombinant mouse (rm) VEGFR1 and rmVEGFR3 is observed.
Source
Polyclonal Goat IgG
Purification
Antigen Affinity-purified
Immunogen
Mouse myeloma cell line NS0-derived recombinant mouse VEGFR2
Ala20-Glu762
Accession # P35918
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Western Blot
0.1 µg/mL
Recombinant Mouse VEGFR2/KDR/Flk‑1 Fc Chimera (Catalog # 443-KD)
Flow Cytometry
2.5 µg/106 cells
bEnd.3 mouse endothelioma cell line
Immunohistochemistry
5-15 µg/mL
See below
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 
Neutralization
Measured by its ability to neutralize VEGFR2/KDR/Flk‑1-mediated inhibition of proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND50) is typically 0.1-0.3 µg/mL in the presence of 50 ng/mL Recombinant Mouse VEGFR2/KDR/Flk‑1 Fc Chimera and 5 ng/mL Recombinant Mouse VEGF164.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Examples

Immunohistochemistry VEGFR2/KDR/Flk‑1 in Mouse Embryo. View Larger

VEGFR2/KDR/Flk‑1 in Mouse Embryo. VEGFR2/KDR/Flk-1 was detected in immersion fixed frozen sections of mouse embryo (14 d.p.c.) using 15 µg/mL Goat Anti-Mouse VEGFR2/KDR/Flk-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF644) overnight at 4 °C. Tissue was stained with the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific labeling was localized to mesenchymal cells. View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.

Immunohistochemistry VEGFR2 in Mouse Kidney Tissue. View Larger

VEGFR2 in Mouse Kidney Tissue. VEGFR2 was detected in acetone fixed cryosections of mouse kidney tissue using Goat Anti-Mouse VEGFR2/KDR/Flk-1 Polyclonal Antibody (Catalog # AF644) for 50 minutes at room temperature. Tissues were stained with rabbit anti-goat secondary antibody and HRP polymer-conjugated anti-rabbit IgG followed by AEC+Substrate Chromogen (red) followed by counterstaining with hematoxylin (blue). Experiments were carried out and the image was provided by Dr. Grietje Molema, University Medical Center Groningen, The Netherlands.

Neutralization VEGFR2/KDR/Flk‑1 Inhibition of VEGF-dependent Cell Proliferation and Neutralization by Mouse VEGFR2/KDR/Flk‑1 Antibody. View Larger

VEGFR2/KDR/Flk‑1 Inhibition of VEGF-dependent Cell Proliferation and Neutralization by Mouse VEGFR2/KDR/Flk‑1 Antibody. Recombinant Mouse VEGFR2/KDR/Flk-1 Fc Chimera (Catalog # 443-KD) inhibits Recombinant Mouse VEGF164(Catalog # 493-MV) induced proliferation in HUVEC human umbilical vein endothelial cells in a dose-dependent manner (orange line). Inhibition of Recombinant Mouse VEGF164(5 ng/mL) activity elicited by Recombinant Mouse VEGFR2/KDR/Flk-1 Fc Chimera (50 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse VEGFR2/KDR/Flk-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF644). The ND50is typically 0.1-0.3 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR2/KDR/Flk-1

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1), and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

Mouse VEGFR2 cDNA encodes a 1367 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 743 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 583 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2/Fc chimera binds VEGF with high affinity and is a potent VEGF antagonist.

References
  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
  2. Achen, M.G. et al. (1998) Proc. Natl. Acad. Sci. USA 95:548.
Long Name
Vascular Endothelial Growth Factor Receptor 2
Entrez Gene IDs
3791 (Human); 16542 (Mouse)
Alternate Names
CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2

Product Datasheets

Citations for Mouse VEGFR2/KDR/Flk-1 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

48 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. EphrinB2 regulates VEGFR2 during dendritogenesis and hippocampal circuitry development
    Authors: E Harde, L Nicholson, B Furones Cu, D Bissen, S Wigge, S Urban, M Segarra, C Ruiz de Al, A Acker-Palm
    Elife, 2019;8(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  2. Disrupting Myelin-Specific Th17 Cell Gut Homing Confers Protection in an Adoptive Transfer Experimental Autoimmune Encephalomyelitis
    Authors: D Duc, S Vigne, J Bernier-La, Y Yersin, F Ruiz, N Gaïa, S Leo, V Lazarevic, J Schrenzel, TV Petrova, C Pot
    Cell Rep, 2019;29(2):378-390.e4.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  3. Endothelial Calcineurin Signaling Restrains Metastatic Outgrowth by Regulating Bmp2
    Authors: S Hendrikx, S Coso, B Prat-Luri, L Wetterwald, A Sabine, CA Franco, S Nassiri, N Zangger, H Gerhardt, M Delorenzi, TV Petrova
    Cell Rep, 2019;26(5):1227-1241.e6.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  4. Endothelial deletion of Ino80 disrupts coronary angiogenesis and causes congenital heart disease
    Authors: S Rhee, JI Chung, DA King, G D'amato, DT Paik, A Duan, A Chang, D Nagelberg, B Sharma, Y Jeong, M Diehn, JC Wu, AJ Morrison, K Red-Horse
    Nat Commun, 2018;9(1):368.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  5. Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors
    Authors: CJ Drummond, JA Hanna, MR Garcia, DJ Devine, AJ Heyrana, D Finkelstei, JE Rehg, ME Hatley
    Cancer Cell, 2018;33(1):108-124.e5.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  6. Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality
    Authors: IK Kim, K Kim, E Lee, DS Oh, CS Park, S Park, JM Yang, JH Kim, HS Kim, DT Shima, JH Kim, SH Hong, YH Cho, YH Kim, JB Park, GY Koh, YS Ju, HK Lee, S Lee, I Kim
    J. Exp. Med., 2018;0(0):.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: IHC-P
  7. Deletion of Nkx2-5 in trabecular myocardium reveals the developmental origins of pathological heterogeneity associated with ventricular non-compaction cardiomyopathy
    Authors: C Choquet, THM Nguyen, P Sicard, E Buttigieg, TT Tran, F Kober, I Varlet, R Sturny, MW Costa, RP Harvey, C Nguyen, P Rihet, S Richard, M Bernard, RG Kelly, N Lalevée, L Miquerol
    PLoS Genet., 2018;14(7):e1007502.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  8. In utero electroporation induces cell death and alters embryonic microglia morphology and expression signatures in the developing hypothalamus
    Authors: JM Rosin, DM Kurrasch
    J Neuroinflammation, 2018;15(1):181.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  9. Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia
    Authors: JL Sones, AA Merriam, A Seffens, DA Brown-Gran, SD Butler, AM Zhao, X Xu, CJ Shawber, JK Grenier, NC Douglas
    FASEB J., 2017;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  10. Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma
    Authors: J Kim, DY Park, H Bae, DY Park, D Kim, CK Lee, S Song, TY Chung, DH Lim, Y Kubota, YK Hong, Y He, HG Augustin, G Oliver, GY Koh
    J. Clin. Invest., 2017;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  11. Retinoic acid-induced upregulation of miR-219 promotes the differentiation of embryonic stem cells into neural cells
    Authors: H Wu, J Zhao, B Fu, S Yin, C Song, J Zhang, S Zhao, Y Zhang
    Cell Death Dis, 2017;8(7):e2953.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Western Blot
  12. VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling
    Authors: K Heinolaine, S Karaman, G D'Amico, T Tammela, R Sormunen, L Eklund, K Alitalo, G Zarkada
    Circ. Res, 2017;0(0):.
    Species: Mouse
    Sample Types: Tissue Homogenates
    Applications: Western Blot
  13. Generation of iPSC-derived limb progenitor-like cells for stimulating phalange regeneration in the adult mouse
    Authors: Y Chen, H Xu, G Lin
    Cell Discov, 2017;3(0):17046.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  14. Cell-matrix signals specify bone endothelial cells during developmental osteogenesis
    Authors: UH Langen, ME Pitulescu, JM Kim, R Enriquez-G, KK Sivaraj, AP Kusumbe, A Singh, J Di Russo, MG Bixel, B Zhou, L Sorokin, JM Vaquerizas, RH Adams
    Nat. Cell Biol, 2017;19(3):189-201.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  15. Pdgfrb-Cre targets lymphatic endothelial cells of both venous and non-venous origins
    Authors: MH Ulvmar, I Martinez-C, L Stanczuk, T Mäkinen
    Genesis, 2016;0(0):.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  16. Slit2 signaling through Robo1 and Robo2 is required for retinal neovascularization.
    Authors: Rama N, Dubrac A, Mathivet T, Ni Charthaigh R, Genet G, Cristofaro B, Pibouin-Fragner L, Ma L, Eichmann A, Chedotal A
    Nat Med, 2015;21(5):483-91.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  17. Neural crest-derived SEMA3C activates endothelial NRP1 for cardiac outflow tract septation.
    Authors: Plein A, Calmont A, Fantin A, Denti L, Anderson N, Scambler P, Ruhrberg C
    J Clin Invest, 2015;125(7):2661-76.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  18. Semaphorin3A elevates vascular permeability and contributes to cerebral ischemia-induced brain damage.
    Authors: Hou, Sheng Ta, Nilchi, Ladan, Li, Xuesheng, Gangaraju, Sandhya, Jiang, Susan X, Aylsworth, Amy, Monette, Robert, Slinn, Jacqueli
    Sci Rep, 2015;5(0):7890.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Bioassay
  19. The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel.
    Authors: Aspelund A, Tammela T, Antila S, Nurmi H, Leppanen V, Zarkada G, Stanczuk L, Francois M, Makinen T, Saharinen P, Immonen I, Alitalo K
    J Clin Invest, 2014;124(9):3975-86.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  20. The role of IL-1beta in the early tumor cell-induced angiogenic response.
    Authors: Carmi Y, Dotan S, Rider P, Kaplanov I, White M, Baron R, Abutbul S, Huszar M, Dinarello C, Apte R, Voronov E
    J Immunol, 2013;190(7):3500-9.
  21. Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma.
    Authors: Song K, Herzog B, Sheng M, Fu J, McDaniel J, Chen H, Ruan J, Xia L
    Cancer Res, 2013;73(24):7254-64.
    Species: Human
    Sample Types: Tissue Homogenates
    Applications: Western Blot
  22. KDR identifies a conserved human and murine hepatic progenitor and instructs early liver development.
    Authors: Goldman O, Han S, Sourisseau M, Dziedzic N, Hamou W, Corneo B, D'Souza S, Sato T, Kotton D, Bissig K, Kalir T, Jacobs A, Evans T, Evans M, Gouon-Evans V
    Cell Stem Cell, 2013;12(6):748-60.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  23. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling.
    Authors: Benedito R, Rocha S, Woeste M, Zamykal M, Radtke F, Casanovas O, Duarte A, Pytowski B, Adams R
    Nature, 2012;484(7392):110-4.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: ELISA Development
  24. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd.
    Authors: Sun Z, Li X, Massena S, Kutschera S, Padhan N, Gualandi L, Sundvold-Gjerstad V, Gustafsson K, Choy WW, Zang G, Quach M, Jansson L, Phillipson M, Abid MR, Spurkland A, Claesson-Welsh L
    J. Exp. Med., 2012;209(7):1363-77.
    Species: Mouse
    Sample Types: Tissue Homogenates
    Applications: Western Blot
  25. The adaptation of the blood-brain barrier to vascular endothelial growth factor and placental growth factor during pregnancy.
    Authors: Schreurs MP, Houston EM, May V, Cipolla MJ
    FASEB J., 2012;26(1):355-62.
    Species: Rat
    Sample Types: In Vivo
    Applications: Neutralization
  26. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy.
    Authors: Efe JA, Hilcove S, Kim J, Zhou H, Ouyang K, Wang G, Chen J, Ding S
    Nat. Cell Biol., 2011;13(3):215-22.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: ICC
  27. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis.
    Authors: Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, Acker-Palmer A
    Nature, 2010;465(7297):487-91.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation
  28. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
    Authors: Lohela M, Helotera H, Haiko P, Dumont DJ, Alitalo K
    Am. J. Pathol., 2008;173(6):1891-901.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  29. Tumor necrosis factor-alpha and endothelial cells modulate Notch signaling in the bone marrow microenvironment during inflammation.
    Authors: Fernandez L, Rodriguez S, Huang H, Chora A, Fernandes J, Mumaw C, Cruz E, Pollok K, Cristina F, Price JE, Ferkowicz MJ, Scadden DT, Clauss M, Cardoso AA, Carlesso N
    Exp. Hematol., 2008;36(5):545-558.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-P
  30. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
    Authors: Tammela T, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Yla-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K
    Nature, 2008;454(7204):656-60.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  31. Chronic hydrocephalus-induced hypoxia: increased expression of VEGFR-2+ and blood vessel density in hippocampus.
    Authors: Dombrowski SM, Deshpande A, Dingwall C, Leichliter A, Leibson Z, Luciano MG
    Neuroscience, 2007;152(2):346-59.
    Species: Canine
    Sample Types: Whole Tissue
    Applications: IHC-Fr
  32. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.
    Authors: Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S
    Cancer Res., 2007;67(12):5789-97.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC-P
  33. Lentiviral rescue of vascular endothelial growth factor receptor-2 expression in flk1-/- embryonic stem cells shows early priming of endothelial precursors.
    Authors: Li X, Edholm D, Lanner F, Breier G, Farnebo F, Dimberg A, Claesson-Welsh L
    Stem Cells, 2007;25(12):2987-95.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation
  34. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.
    Authors: Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Yla-Herttuala S, Shibuya M, Alitalo K
    J. Exp. Med., 2007;204(6):1431-40.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC
  35. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor.
    Authors: Depeille P, Young JJ, Boguslawski EA, Berghuis BD, Kort EJ, Resau JH, Frankel AE, Duesbery NS
    Clin. Cancer Res., 2007;13(19):5926-34.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: ICC
  36. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A.
    Authors: Nozaki M, Sakurai E, Raisler BJ, Baffi JZ, Witta J, Ogura Y, Brekken RA, Sage EH, Ambati BK, Ambati J
    J. Clin. Invest., 2006;116(2):422-9.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Immunoprecipitation
  37. Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2.
    Authors: Yamaji-Kegan K, Su Q, Angelini DJ, Champion HC, Johns RA
    Am. J. Physiol. Lung Cell Mol. Physiol., 2006;291(6):L1159-68.
    Species: Mouse
    Sample Types: In Vivo
    Applications: Neutralization
  38. Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice.
    Authors: Schmitz V, Vilanueva H, Raskopf E, Hilbert T, Barajas M, Dzienisowicz C, Gorschluter M, Strehl J, Rabe C, Sauerbruch T, Prieto J, Caselmann WH, Qian C
    Gene Ther., 2006;13(16):1198-205.
    Species: Mouse
    Sample Types: Serum
    Applications: Western Blot
  39. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro.
    Authors: Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, Wang J, Ling V, Sun L
    Chem. Biol., 2006;13(5):549-56.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  40. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
    Authors: Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG
    Cancer Res., 2006;66(22):10919-28.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Neutralization
  41. Antagonism of vascular endothelial growth factor results in microvessel attrition and disorganization of wound tissue.
    Authors: Gudehithlu KP, Ahmed N, Wu H, Litbarg NO, Garber SL, Arruda JA, Dunea G, Singh AK
    J. Lab. Clin. Med., 2005;145(4):194-203.
    Species: Rat
    Sample Types: Whole Tissue
    Applications: IHC-P
  42. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation.
    Authors: Dikov MM, Ohm JE, Ray N, Tchekneva EE, Burlison J, Moghanaki D, Nadaf S, Carbone DP
    J. Immunol., 2005;174(1):215-22.
    Species: Mouse
    Sample Types: Cell Lysates
    Applications: Western Blot
  43. Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model.
    Authors: Raskopf E, Dzienisowicz C, Hilbert T, Rabe C, Leifeld L, Wernert N, Sauerbruch T, Prieto J, Qian C, Caselmann WH, Schmitz V
    Hepatology, 2005;41(6):1233-40.
    Species: Mouse
    Sample Types: Serum
    Applications: ELISA Development
  44. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells.
    Authors: Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E
    Leuk. Res., 2004;28(3):243-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: ICC
  45. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.
    Authors: Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C
    J. Cell Biol., 2003;161(6):1163-77.
    Species: Rat
    Sample Types: In Vivo
    Applications: Neutralization
  46. Vascular endothelial growth factor-B promotes in vivo angiogenesis.
    Authors: Silvestre JS, Tamarat R, Ebrahimian TG, Le-Roux A, Clergue M, Emmanuel F, Duriez M, Schwartz B, Branellec D, Levy BI
    Circ. Res., 2003;93(2):114-23.
    Species: Mouse
    Sample Types: In Vivo
    Applications: Neutralization
  47. Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction.
    Authors: Kozawa O, Yoshimi N, Akamatsu S, Hara A, Mori H, Uematsu T
    Blood, 2002;100(7):2487-93.
    Species: Mouse
    Sample Types: In Vivo
    Applications: Neutralization
  48. The embryonic mouse hindbrain as a qualitative and quantitative model for studying the molecular and cellular mechanisms of angiogenesis.
    Authors: Fantin A, Vieira J, Plein A, Maden C, Ruhrberg C
    Nat Protoc, 0;8(2):418-29.
    Species: Mouse
    Sample Types: Whole Tissue
    Applications: IHC

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Cell and Tissue Staining Kits

Immunohistochemistry Reagents

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Mouse VEGFR2/KDR/Flk-1 Antibody

There are currently no reviews for this product. Be the first to review Mouse VEGFR2/KDR/Flk-1 Antibody and earn rewards!

Have you used Mouse VEGFR2/KDR/Flk-1 Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review